boulardii supplementation induces therapeutic improvement for inflammatory bowel disease (IBD) [190], diarrhea [191,192] and ulcerative colitis (UC) settings [193,194] by pro-inflammatory cytokine inhibition via NF-κB and ERK/1 pathway impairment, and by directly suppressing bacteria overgrowth and, as previously mentioned, cleavage of C. difficile toxins [195]. This evidence concerns the gene NFKB1 and inflammatory bowel disease.